Bevirimat
Bevirimat
Bevirimat (pronunciation: be-vi-ri-mat) is an experimental antiretroviral drug that was under development for the treatment of HIV infection. It belongs to a class of drugs known as maturation inhibitors, which work by preventing the virus from reaching its mature, infectious form.
Etymology
The name "Bevirimat" is derived from the words "bevi" and "mat", which are abbreviations for "beverage" and "maturation" respectively. This is a reference to the drug's method of administration (as a liquid) and its mechanism of action (inhibiting the maturation of the HIV virus).
Mechanism of Action
Bevirimat works by binding to the Gag protein, a key component of the HIV virus. This prevents the Gag protein from being cleaved into its final components, thus stopping the virus from maturing and becoming infectious.
Development and Clinical Trials
Bevirimat was developed by Panacos Pharmaceuticals, a biotechnology company based in the United States. It underwent Phase II clinical trials, but development was halted in 2010 due to issues with drug formulation and patient response.
Related Terms
External links
- Medical encyclopedia article on Bevirimat
- Wikipedia's article - Bevirimat
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski